Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 19Sarcoma 6Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Endocrine 2Dermatologic 2Thoracic 1NET 1Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Temozolomide × Gynecologic × Clear all
NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Pfizer

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡